Developer docs
API playgroundTry for free, no card

Search company profiles

Atox Bio

Full company profile

uuid0005lmt

Namestring
Atox Bio
Legal namestring
Atox Bio
Websiteurl
atoxbio.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Atox Bio is a privately-held biotechnology company founded in 2003 and headquartered in Ness Ziona, Israel. According to firmographic records, the company specializes in infectious diseases, immunomodulators, and critical care therapeutics — a clinical-stage profile consistent with its investor base and scientific leadership. The company was scientifically founded by immunologists Raymond Kaempfer and Gila Arad, and its clinical development is led by Chief Medical Officer Wayne M Dankner. The company's intellectual and operational foundation is rooted in academic immunology research, with no commercialized products disclosed in the available data.

Atox Bio has raised approximately $58.35M across four documented funding rounds spanning 2010 to 2017, with the largest being a $30M Series C in December 2017 led by Arix Bioscience and backed by a syndicate of tier-one healthcare investors including Adams Street Partners, Asahi Kasei, Integra Holdings, Lundbeckfonden Ventures, OrbiMed, SR One, and The Becker Group. Earlier rounds were led by SR One ($23M in 2014) and Esperante Ventures ($3.25M in 2011). This investor roster is characteristic of a serious clinical-stage biotech rather than a commercial-stage pharmaceutical or consumer-products company, and represents the most authoritative data on what Atox Bio actually does.

A significant portion of the scraped source material describes a direct-to-consumer e-commerce operation (atoxbio.com) selling injectable Human Growth Hormone and GLP-1 peptides (Semaglutide, Tirzepatide, Retatrutide, Ozempic) to global consumers via cryptocurrency and PayPal, with warehouses in the USA and Turkey. This material is internally inconsistent with Atox Bio's biotech identity, scientific founders, investor syndicate, and stated therapeutic focus, and is most plausibly attributable to a domain-name collision, brand impersonation, or an unrelated entity that has acquired the atoxbio.com web address. It has therefore been excluded from the substantive description of the company. Investors evaluating Atox Bio should verify the current use and ownership of the atoxbio.com domain, as the divergence between the firm's documented biotech identity and its live web presence is a material diligence item.

Short descriptiontext

Atox Bio is a privately-held, clinical-stage biotechnology company founded in 2003 in Ness Ziona, Israel, developing immunomodulators for infectious diseases and critical care, backed by approximately $58M from biotech investors including OrbiMed, Arix Bioscience, and SR One.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human growth hormone, online pharmacy retail, peptide therapy products, weight management medications, anti-aging injectables
Industry4 codes
PRIMARYCRAHAEAC
Health Food & Supplement Stores
Consumer Products & Retail/Grocery & Food Retail/Natural/Organic & Health Food Stores
SECONDARYCRADAGAG
Weight Management & Metabolic Supplements
SECONDARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYAFAJAKAG
Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code1 code
  • Food (Health) Supplement Retailers456191
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Online HGH and Peptide Retail
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Direct one-time sales of HGH products (Zptropin, Spectros, Genotropin, Somatropin, Cinnatropin), GLP-1 medications (Semaglutide, Tirzepatide, Retatrutide, Ozempic), and related pharmaceuticals through e-commerce storefront. Products sold at varying price points with discounts on select items.

atoxbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel
Pricing details2 tiers
1HGH Products - Price range from $125 to $610
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Zptropin 200 IU (USA domestic): $420.00 | Spectros 280 IU (USA domestic): $610.00 | Ngenla 72 IU: $385.00 | Somatropin 191aa 150 IU (USA domestic): $365.00 | Zptropin 160 IU (USA domestic): $385.00 | Spectros 140 IU (USA domestic): $305.00 | Genotropin 36 IU pen: $340.00 | Cinnatropin 30 IU: $125.00

atoxbio.com
2GLP-1 Medications - Price range from $135 to $390
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Retatrutide Premixed Pen 30 mg: $325.00 | Tirzepatide Premixed Pen 30 mg (USA domestic): $295.00 | Ozempic 1 mg (USA Domestic): $390.00 | Semaglutide 5 mg: $199.00 | Semaglutide 2 mg: $135.00

atoxbio.com
GTM typeB2C
B2C
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

Atox Bio sells pharmaceutical-grade injectable Human Growth Hormone (HGH) kits and pens (Zptropin, Spectros, Ngenla, Somatropin 191aa, Genotropin, Cinnatropin, ZPtrop AQ) along with GLP-1/metabolic peptide products (Semaglutide, Ozempic, Tirzepatide, Retatrutide) directly to individual consumers worldwide through its online storefront at atoxbio.com. Products are positioned for hormone deficiency therapy, bodybuilding/recovery, anti-aging, and weight management, with anti-counterfeit verification systems and published lab purity results as trust mechanisms.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Atox Bio operates as an online pharmacy and retailer specializing in pharmaceutical-grade injectable Human Growth Hormone (HGH) products and metabolic peptides. The product portfolio includes multiple HGH brands (Zptropin, Spectros, Ngenla, Somatropin 191aa, Genotropin, Cinnatropin, ZPtrop AQ pen) along with GLP-1 and related peptide products (Semaglutide, Ozempic, Tirzepatide, Retatrutide). Products are sourced from both USA domestic and international manufacturers/suppliers, with some brands originating from Turkish pharmacies. The company offers these products for purposes including hormone deficiency therapy, bodybuilding, anti-aging, and weight management. Pricing ranges from budget-friendly options to premium pharmaceutical formulations, with products tested for purity levels of approximately 96-99%.

Product and service14 records
1Zptropin 200 IU kit (USA domestic)
CategoryHGH Product
Description

Human growth hormone kit in 200 IU dosage, sourced from Chinese manufacturers with anti-counterfeit verification codes; priced at $420 on the USA-domestic storefront.

2Spectros 280 IU kit (USA domestic)
CategoryHGH Product
Description

High-dose HGH kit (280 IU) from Spectrum-Pharma, with security hologram and manufacturer verification code; priced at $610 on the USA-domestic storefront.

3Zptropin 160 IU kit (USA domestic)
CategoryHGH Product
Description

Human growth hormone kit in 160 IU dosage, sourced from Chinese manufacturers with anti-counterfeit verification codes; priced at $385 on the USA-domestic storefront.

4Spectros 140 IU kit (USA domestic)
CategoryHGH Product
Description

Spectrum-Pharma HGH kit in 140 IU dosage, with security hologram and verification code; priced at $305 on the USA-domestic storefront.

5Ngenla 72 IU (Long-acting HGH)
CategoryHGH Product
Description

Long-acting HGH formulation in 72 IU dose designed for sustained-release delivery; priced at $385.

6Somatropin 191aa 150 IU kit (USA domestic)
CategoryHGH Product
Description

Biosynthetic human growth hormone (191 amino acid sequence, identical to naturally occurring HGH) in 150 IU kit; priced at $365 on the USA-domestic storefront, with Canadian Peptides manufacturer verification.

7Genotropin 36 IU (12 mg) pen
CategoryHGH Product
Description

Pen-form HGH product with 36 IU / 12 mg dosage, sourced from licensed Turkish pharmacies and verified via QR code through the Turkish Pharmacy Verification System; priced at $340 (limited supply).

8Cinnatropin 30 IU
CategoryHGH Product
Description

Budget-tier HGH product in 30 IU dose, flagged as a bestseller with 9–16 day international delivery; priced at $125.

9ZPtrop AQ 36 IU Pen (USA domestic)
CategoryHGH Product
Description

Pen-form HGH delivery system with 36 IU capacity, featuring 60 clicks with each click delivering 0.2 mg (0.6 IU).

10Semaglutide 5 mg
CategoryPeptide Product
Description

GLP-1 receptor agonist peptide in 5 mg dose for weight management and metabolic support; priced at $199.

11Semaglutide 2 mg
CategoryPeptide Product
Description

Lower-dose GLP-1 receptor agonist peptide (2 mg) for weight management and metabolic support; priced at $135.

12Ozempic 1 mg (USA Domestic)
CategoryPeptide Product
Description

Semaglutide-based injectable medication in 1 mg dose for metabolic and weight management purposes; priced at $390 with 2–4 day USA domestic delivery.

13Tirzepatide Premixed Pen 30 mg (USA domestic)
CategoryPeptide Product
Description

Dual GIP/GLP-1 receptor agonist peptide delivered as a premixed pen in 30 mg dose; priced at $295.

14Retatrutide Premixed Pen 30 mg
CategoryPeptide Product
Description

Triple-agonist peptide (GIP/GLP-1/glucagon) delivered as a premixed pen in 30 mg dose for metabolic support; priced at $325.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthers
Description

Spectros brand manufacturer providing anti-counterfeit verification through spectrum-pharma.com for authenticity checking of Spectros HGH products sold on AtoxBio

Strategic tierMinorTypeOthers
Description

ZPHC manufacturer providing verification system at zphc.hk for authenticating Zptropin HGH products sold through AtoxBio

3Canadian Peptides (Somatropin 191aa)
Strategic tierMinorTypeOthers
Description

Somatropin 191aa manufacturer with verification system at check-canadapeptides.org for product authenticity verification

atoxbio.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers5 records
TypeBroad incumbent
Description

Public online health platform (HIMS) that dispenses prescription HGH and selected peptides through licensed telehealth. Comparable as a consumer-facing online channel for hormone therapy, though operating strictly within US prescription frameworks versus Atox Bio's self-serve model.

2Ro
TypeBroad incumbent
Description

Large online pharmacy and telehealth provider offering men's health, hormone optimization, and weight-loss treatments. Overlaps on the HGH/peptide customer segment but enforces prescription workflows Atox Bio does not, making it the dominant legitimate alternative.

TypeDirect peer
Description

Online men's health clinic offering HGH, testosterone, and peptide therapies through telehealth consultation. Closest direct peer to Atox Bio's HGH-led product mix, with comparable target buyer and peptide category extension, though more structured prescription pathways.

TypeDirect peer
Description

Telehealth clinic focused on hormone optimization, anti-aging, and wellness therapies including HGH and peptides. Comparable in targeting the same off-label/anti-aging buyer persona as Atox Bio via an online-first model.

TypeDirect peer
Description

Direct-to-consumer men's health brand providing hormone testing and HGH/peptide therapy through telehealth. Comparable as a brand-led, online-first challenger competing for the same self-directed consumer HGH buyer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atox Bio

Online HGH and Peptide Retailatoxbio.com

Atox Bio is a privately-held, clinical-stage biotechnology company founded in 2003 in Ness Ziona, Israel, developing immunomodulators for infectious diseases and critical care, backed by approximately $58M from biotech investors including OrbiMed, Arix Bioscience, and SR One.

What Atox Bio does

Atox Bio is a privately-held biotechnology company founded in 2003 and headquartered in Ness Ziona, Israel. According to firmographic records, the company specializes in infectious diseases, immunomodulators, and critical care therapeutics — a clinical-stage profile consistent with its investor base and scientific leadership. The company was scientifically founded by immunologists Raymond Kaempfer and Gila Arad, and its clinical development is led by Chief Medical Officer Wayne M Dankner. The company's intellectual and operational foundation is rooted in academic immunology research, with no commercialized products disclosed in the available data.

Atox Bio has raised approximately $58.35M across four documented funding rounds spanning 2010 to 2017, with the largest being a $30M Series C in December 2017 led by Arix Bioscience and backed by a syndicate of tier-one healthcare investors including Adams Street Partners, Asahi Kasei, Integra Holdings, Lundbeckfonden Ventures, OrbiMed, SR One, and The Becker Group. Earlier rounds were led by SR One ($23M in 2014) and Esperante Ventures ($3.25M in 2011). This investor roster is characteristic of a serious clinical-stage biotech rather than a commercial-stage pharmaceutical or consumer-products company, and represents the most authoritative data on what Atox Bio actually does.

A significant portion of the scraped source material describes a direct-to-consumer e-commerce operation (atoxbio.com) selling injectable Human Growth Hormone and GLP-1 peptides (Semaglutide, Tirzepatide, Retatrutide, Ozempic) to global consumers via cryptocurrency and PayPal, with warehouses in the USA and Turkey. This material is internally inconsistent with Atox Bio's biotech identity, scientific founders, investor syndicate, and stated therapeutic focus, and is most plausibly attributable to a domain-name collision, brand impersonation, or an unrelated entity that has acquired the atoxbio.com web address. It has therefore been excluded from the substantive description of the company. Investors evaluating Atox Bio should verify the current use and ownership of the atoxbio.com domain, as the divergence between the firm's documented biotech identity and its live web presence is a material diligence item.

Atox Bio firmographics

Firmographics
Name
Atox Bio
Legal name
Atox Bio
Website
https://atoxbio.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
1–10 employees
Short description
Atox Bio is a privately-held, clinical-stage biotechnology company founded in 2003 in Ness Ziona, Israel, developing immunomodulators for infectious diseases and critical care, backed by approximately $58M from biotech investors including OrbiMed, Arix Bioscience, and SR One.
Ownership category
akta.pro rank

Atox Bio industry classification

Industry
Product category
Online HGH and Peptide Retail
NAICS
Food (Health) Supplement Retailers (456191)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRAHAEAC
Health Food & Supplement Stores
Consumer Products & Retail/Grocery & Food Retail/Natural/Organic & Health Food Stores
SECONDARYCRADAGAG
Weight Management & Metabolic Supplements
SECONDARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYAFAJAKAG
Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Human growth hormone
  • Online pharmacy retail
  • Peptide therapy products
  • Weight management medications
  • Anti-aging injectables

Where Atox Bio is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Atox Bio business model

Business model
GTM type
B2C
Offering type
Digital Commerce or Content
Cost components
Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel

Revenue model

  1. Pharmaceutical Product Sales: Direct one-time sales of HGH products (Zptropin, Spectros, Genotropin, Somatropin, Cinnatropin), GLP-1 medications (Semaglutide, Tirzepatide, Retatrutide, Ozempic), and related pharmaceuticals through e-commerce storefront. Products sold at varying price points with discounts on select items.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHGH Products - Price range from $125 to $610
Unit PricingPay-as-you-goGLP-1 Medications - Price range from $135 to $390

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Atox Bio product offering

Product offering

Core offering

Atox Bio sells pharmaceutical-grade injectable Human Growth Hormone (HGH) kits and pens (Zptropin, Spectros, Ngenla, Somatropin 191aa, Genotropin, Cinnatropin, ZPtrop AQ) along with GLP-1/metabolic peptide products (Semaglutide, Ozempic, Tirzepatide, Retatrutide) directly to individual consumers worldwide through its online storefront at atoxbio.com. Products are positioned for hormone deficiency therapy, bodybuilding/recovery, anti-aging, and weight management, with anti-counterfeit verification systems and published lab purity results as trust mechanisms.

Product overview

Atox Bio operates as an online pharmacy and retailer specializing in pharmaceutical-grade injectable Human Growth Hormone (HGH) products and metabolic peptides. The product portfolio includes multiple HGH brands (Zptropin, Spectros, Ngenla, Somatropin 191aa, Genotropin, Cinnatropin, ZPtrop AQ pen) along with GLP-1 and related peptide products (Semaglutide, Ozempic, Tirzepatide, Retatrutide). Products are sourced from both USA domestic and international manufacturers/suppliers, with some brands originating from Turkish pharmacies. The company offers these products for purposes including hormone deficiency therapy, bodybuilding, anti-aging, and weight management. Pricing ranges from budget-friendly options to premium pharmaceutical formulations, with products tested for purity levels of approximately 96-99%.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zptropin 200 IU kit (USA domestic) Human growth hormone kit in 200 IU dosage, sourced from Chinese manufacturers with anti-counterfeit verification codes; priced at $420 on the USA-domestic storefront.
  • Spectros 280 IU kit (USA domestic) High-dose HGH kit (280 IU) from Spectrum-Pharma, with security hologram and manufacturer verification code; priced at $610 on the USA-domestic storefront.
  • Zptropin 160 IU kit (USA domestic) Human growth hormone kit in 160 IU dosage, sourced from Chinese manufacturers with anti-counterfeit verification codes; priced at $385 on the USA-domestic storefront.
  • Spectros 140 IU kit (USA domestic) Spectrum-Pharma HGH kit in 140 IU dosage, with security hologram and verification code; priced at $305 on the USA-domestic storefront.
  • Ngenla 72 IU (Long-acting HGH) Long-acting HGH formulation in 72 IU dose designed for sustained-release delivery; priced at $385.
  • Somatropin 191aa 150 IU kit (USA domestic) Biosynthetic human growth hormone (191 amino acid sequence, identical to naturally occurring HGH) in 150 IU kit; priced at $365 on the USA-domestic storefront, with Canadian Peptides manufacturer verification.
  • Genotropin 36 IU (12 mg) pen Pen-form HGH product with 36 IU / 12 mg dosage, sourced from licensed Turkish pharmacies and verified via QR code through the Turkish Pharmacy Verification System; priced at $340 (limited supply).
  • Cinnatropin 30 IU Budget-tier HGH product in 30 IU dose, flagged as a bestseller with 9–16 day international delivery; priced at $125.
  • ZPtrop AQ 36 IU Pen (USA domestic) Pen-form HGH delivery system with 36 IU capacity, featuring 60 clicks with each click delivering 0.2 mg (0.6 IU).
  • Semaglutide 5 mg GLP-1 receptor agonist peptide in 5 mg dose for weight management and metabolic support; priced at $199.
  • Semaglutide 2 mg Lower-dose GLP-1 receptor agonist peptide (2 mg) for weight management and metabolic support; priced at $135.
  • Ozempic 1 mg (USA Domestic) Semaglutide-based injectable medication in 1 mg dose for metabolic and weight management purposes; priced at $390 with 2–4 day USA domestic delivery.
  • Tirzepatide Premixed Pen 30 mg (USA domestic) Dual GIP/GLP-1 receptor agonist peptide delivered as a premixed pen in 30 mg dose; priced at $295.
  • Retatrutide Premixed Pen 30 mg Triple-agonist peptide (GIP/GLP-1/glucagon) delivered as a premixed pen in 30 mg dose for metabolic support; priced at $325.

Companies that use Atox Bio

Customer profile

Segments4 records

Ideal customer profiles3 records

Atox Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Atox Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • Spectrum-Pharma (Spectros)minorOthersSpectros brand manufacturer providing anti-counterfeit verification through spectrum-pharma.com for authenticity checking of Spectros HGH products sold on AtoxBio
  • ZPHC (Zptropin)minorOthersZPHC manufacturer providing verification system at zphc.hk for authenticating Zptropin HGH products sold through AtoxBio
  • Canadian Peptides (Somatropin 191aa)minorOthersSomatropin 191aa manufacturer with verification system at check-canadapeptides.org for product authenticity verification

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Atox Bio competitors and assessment

Company assessment

Broad incumbents

  • Hims & Hers Health: Public online health platform (HIMS) that dispenses prescription HGH and selected peptides through licensed telehealth. Comparable as a consumer-facing online channel for hormone therapy, though operating strictly within US prescription frameworks versus Atox Bio's self-serve model.
  • Ro: Large online pharmacy and telehealth provider offering men's health, hormone optimization, and weight-loss treatments. Overlaps on the HGH/peptide customer segment but enforces prescription workflows Atox Bio does not, making it the dominant legitimate alternative.

Direct peers

  • Invigor Medical: Online men's health clinic offering HGH, testosterone, and peptide therapies through telehealth consultation. Closest direct peer to Atox Bio's HGH-led product mix, with comparable target buyer and peptide category extension, though more structured prescription pathways.
  • Defy Medical: Telehealth clinic focused on hormone optimization, anti-aging, and wellness therapies including HGH and peptides. Comparable in targeting the same off-label/anti-aging buyer persona as Atox Bio via an online-first model.
  • Marek Health: Direct-to-consumer men's health brand providing hormone testing and HGH/peptide therapy through telehealth. Comparable as a brand-led, online-first challenger competing for the same self-directed consumer HGH buyer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Atox Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atox Bio leadership team

Management profile

Number of profiles

Profiles3 records

Atox Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atox Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atox Bio

What does Atox Bio do?

Atox Bio sells pharmaceutical-grade injectable Human Growth Hormone (HGH) kits and pens (Zptropin, Spectros, Ngenla, Somatropin 191aa, Genotropin, Cinnatropin, ZPtrop AQ) along with GLP-1/metabolic peptide products (Semaglutide, Ozempic, Tirzepatide, Retatrutide) directly to individual consumers worldwide through its online storefront at atoxbio.com. Products are positioned for hormone deficiency therapy, bodybuilding/recovery, anti-aging, and weight management, with anti-counterfeit verification systems and published lab purity results as trust mechanisms.

Is Atox Bio a public or private company?

Atox Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Atox Bio founded?

Atox Bio was founded in 2003. It employs 1 to 10 people.

Where is Atox Bio based?

Atox Bio is headquartered in Ness Ziona, Israel, in the Middle East region.

How does Atox Bio make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Atox Bio's main competitors?

Broad incumbents on record are Hims & Hers Health and Ro. Direct peers are Invigor Medical, Defy Medical and Marek Health.

Does Atox Bio have an API?

No public API is recorded for Atox Bio.

What industry is Atox Bio in?

Atox Bio's product category is Online HGH and Peptide Retail. Its primary akta.pro industry code is CRAHAEAC, Health Food & Supplement Stores, with a secondary code of CRADAGAG, Weight Management & Metabolic Supplements. Its NAICS code is 456191 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAtox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease")Atox Bio announced on December 10, 2020, that the U.S. FDA has accepted to file the New Drug Application for reltecimod, with a PDUFA target date set for September 30, 2021, for treating suspected organ dysfunction or failure in patients aged 12 and older with necrotizing soft tissue infection. The proposed treatment was submitted under the FDA's Accelerated Approval Program based on results from the ACCUTE Phase 3 trial, which enrolled 290 patients across sites in the US and France. If approved, reltecimod would become the first therapy specifically approved for NSTI, a rare life-threatening disease affecting approximately 30,000 patients annually in the US alone, currently treated without any approved drug therapy.GlobeNewswireAtox Bio Announces a Positive Effect of Reltecimod onAtox Bio announced Phase 3 ACCUTE trial results for reltecimod in necrotizing soft tissue infection, showing significant resolution of organ dysfunction by Day 14 versus placebo. The company plans to submit an NDA to the FDA in Q3 2020 under the accelerated approval pathway.PR NewswireAtox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTIAtox Bio announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract for the continued development of Reltecimod, the company's lead product, for Necrotizing Soft Tissue Infections (NSTI). The exercise brings BARDA's total commitment to $22 million, covering the pivotal Phase 3 ACCUTE study including manufacturing and regulatory activities, with results expected by the end of 2019. Reltecimod has received Orphan Drug status from the FDA and EMA and Fast Track designation for the NSTI indication, which currently has no approved treatments.PR NewswireAtox Bio Announces Appointment of Robert Greif as Chief Commercial OfficerAtox Bio announced the appointment of Robert Greif as Chief Commercial Officer in a newly created position, where he will lead the commercial organization and pre-commercial activities for Reltecimod, the company's lead product currently in late-stage clinical trials for Necrotizing Soft Tissue Infections and Sepsis-associated Acute Kidney Injury. Results from the ACCUTE Phase 3 study in NSTI are expected by year-end, with the company preparing to potentially launch the first treatment specifically developed for NSTI next year. The appointment is supported by an ongoing contract with BARDA for Reltecimod's NSTI development and backed by investors including SR One, OrbiMed, Lundbeckfonden Ventures, Arix Bioscience plc and Adams Street Partners.PR NewswireAtox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue InfectionsAtox Bio announced that its independent Data Monitoring Committee recommended continuing the Phase 3 ACCUTE trial for Reltecimod without modification after a safety review of the first 200 patients. The drug is being evaluated for treating Necrotizing Soft Tissue Infections, with enrollment ongoing at centers in the U.S. and France. Atox Bio also noted it is conducting a separate Phase 2 study for Reltecimod regarding abdominal sepsis-induced acute kidney injury.PR NewswireAtox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)Atox Bio announced enrollment of the first patient in the Phase 2 REAKT study evaluating Reltecimod for the treatment of Acute Kidney Injury, with 120 patients to be enrolled at approximately 50 level 1 trauma centers across the United States. The randomized, placebo-controlled study will test the drug as a single dose administered within 6 hours of AKI diagnosis, with complete recovery from stage 2/3 AKI as the primary endpoint. AKI affects approximately 3 million patients annually in the US, Europe, and Japan, and there are currently no approved therapies available for the condition.GlobeNewswireArix Bioscience leads $30 million financing for Atox BioArix Bioscience led a $30 million Series F financing round for Atox Bio, investing $8 million for an equity stake. The funds will advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building on ongoing Phase 3 development for necrotising soft tissue infections. Arix Bioscience also met its target of 12 Group Businesses by end of 2017.FinSMEsAtox Bio Closes $30M Funding RoundAtox Bio raised $30M in funding led by Arix Bioscience, with participation from Adams Street Partners and others. The company will use the proceeds to advance its lead product Reltecimod into acute kidney injury, planning a Phase 2 study in 2018. Reltecimod is currently in a Phase 3 study for necrotizing soft tissue infections.GlobesAtox Bio raises $30m to develop kidney injury treatmentAtox Bio raised $30 million in a round led by Arix Bioscience, with participation from Adams Street Partners, Asahi Kasei, and others. The company will use the funds to advance its lead product Reltecimod into acute kidney injury, planning a Phase 2 study in 2018. The round was oversubscribed.VC News DailyAtox Bio Closes $30M InvestmentAtox Bio, a clinical stage biotechnology company based in Chapel Hill, NC, has successfully raised $30 million in a financing round led by Arix Bioscience plc, with participation from several investors including Adams Street Partners and Asahi Kasei Corporation. The funds will be utilized to advance the clinical development of Reltecimod, especially targeting Acute Kidney Injury (AKI) and Necrotizing Soft Tissue Infections (NSTI). Atox Bio plans to initiate a Phase 2 clinical study for AKI in 2018, building on its progress in previous studies.